Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Smoking Research Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01465880
Recruitment Status : Completed
First Posted : November 6, 2011
Last Update Posted : December 21, 2011
Information provided by (Responsible Party):
Philip Morris Products S.A.

Brief Summary:
The purpose of this study is to develop a fit-for-purpose biochemical verification tool that can be used to detect concomitant use of a few (less than 5) conventional cigarettes.

Condition or disease Intervention/treatment Phase
Smoking Non-smoking Other: Part A Not Applicable

Detailed Description:

This study will be performed in two parts. The first part, Part A, is a dose titration study in healthy smokers with incremental cigarette consumption performed in confinement. The second part, Part B, is an observational study on healthy non-smokers in an ambulatory setting

PART A (smokers only)

A screening visit will be conducted within 4 weeks prior to admission to the investigational site. The 8-day confinement period consists of the admission day (Day1), 1 day ad-libitum smoking (Day0), 3 days of smoking abstinence (Day1-3), 2-day exposure period smoking 2 and 4 cigarettes (Day4-5), and the day of discharge (Day6) followed by a 7-day safety follow-up period. Urine collection will be performed for each subject from Day0 to Day5 in 4 intervals.

PART B (non-smokers)

Screening visit will be conducted within 4 weeks prior to the ambulatory Visit 1 (collection of 24-hour urine and spot urine) to the investigational site. The minimum interval between the screening and Visit 1 is of 7 days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 88 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Single-centre, Dose Titration Study in Healthy Volunteers (Smokers and Non-smokers) to Evaluate the Capacity of 2-cyanoethylmercapturic Acid (CEMA) to Detect Low Level of Cigarette Smoking Exposure
Study Start Date : July 2011
Actual Primary Completion Date : November 2011
Actual Study Completion Date : November 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Smoking

Arm Intervention/treatment
No Intervention: Part B. Healthy Caucasian adult non-smokers
Experimental: Part A.Healthy Caucasian adult smokers
No product will be investigated in this study. Smokers will smoke their own conventional cigarettes only.
Other: Part A
Smoking abstinence, smoking 2 and 4 cigarettes

Primary Outcome Measures :
  1. Levels of CEMA, a biomarker of exposure to acrylonitrile, in 24-hour urine of smokers smoking 2 or 4 conventional cigarettes [ Time Frame: After smoking 2 or 4 conventional cigarettes, within 24 hours ]
    To demonstrate that CEMA, used as a urinary biomarker, can identify subjects who have smoked 4 or less conventional cigarettes

Secondary Outcome Measures :
  1. Levels of CEMA in 24-hour urine, carboxyhaemoglobin (COHb) in blood and carbon monoxide in exhaled breath of smokers smoking 2 or 4 conventional cigarettes [ Time Frame: After smoking 2 or 4 conventional cigarettes, within 24 hours ]
    To evaluate the ability of CEMA to detect conventional cigarette use in comparison to COHb and exhaled carbon monoxide

  2. Levels of CEMA, a biomarker of exposure to acrylonitrile, in 24-hour and spot urine of non-smokers [ Time Frame: 24 hours ]
    To evaluate the correlation between the levels of CEMA in 24-hour urine and in spot urine in non-smokers

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   23 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

Common criteria to smokers and non-smokers

  1. Subject is able to understand the information provided in the Subject Information sheet and Informed Consent Form (ICF)
  2. Subject has signed the ICF
  3. Subject of Caucasian origin
  4. Aged from 23 to 55 years
  5. Having acceptable health conditions as judged by the Investigator at the screening visit based on clinical laboratory parameters (clinical biochemistry, urine analysis and standard haematology), spirometry, serology, urine drug screen, vital signs, physical examination, ECG, and medical history

    Specific to smokers

  6. Current smoker based on self-reporting who smoke 5 to 15 commercially available non-mentholated conventional cigarettes (no brand restrictions) with a maximum tar yield of 10 mg (ISO method, as labelled on the cigarette package) smoking at least for the last 3 consecutive years. The smoking status will be verified at screening based on a urinary cotinine test (cotinine ≥200ng/ml)
  7. Subject is willing to smoke according to the smoking regimen of the study

    Specific to non-smokers

  8. Non-smoker based on self-reporting who have not used any tobacco or nicotine containing product including commercially available cigarettes, hand-rolled cigarettes, cigars, pipes, snuff, electronic cigarettes, similar devices, and nicotine replacement therapy within the last 12 months. The non-smoking status of the subject will be verified at screening based on a urinary cotinine test (cotinine <200ng/ml)

Exclusion Criteria:

Common criteria to smokers and non-smokers

  1. As per judgement of the Investigator, any subject who cannot participate in the study for any reason (e.g., medical, psychiatric and/or social reason)
  2. Any clinically relevant gastrointestinal, renal, hepatic, neurological, haematological, endocrine, oncological, urological, immunological and cardiovascular diseases or any other condition including clinically significant abnormal laboratory parameters that, in the opinion of the Investigator, could jeopardise the safety of the subject or impact the validity of the study results
  3. Lung cancer, upper respiratory tract cancers, chronic respiratory diseases or any other clinically significant pulmonary diseases according to the judgement of the Investigator
  4. Any medical conditions requiring smoking cessation (e.g., recent acute cardiovascular event, diabetes mellitus, Chronic Obstructive Pulmonary disease)
  5. Subject with body mass index < 18.5 or ≥ 30 kg/m2
  6. As per judgement of the Investigator, medical conditions which require or will require in the course of the study a medical intervention (e.g., start of treatment, surgery, hospitalisation) which may interfere with the study participation and/or study results
  7. Donation or receipt of whole blood or blood products within 3 months prior to the screening visit
  8. Participation in any clinical studies within 3 months before the screening visit
  9. Current or former employee of the tobacco industry, or of their first-degree relatives (parent, sibling, child)
  10. Employee of the investigational site or any other parties involved in the study or of their first-degree relatives (parent, sibling, child)
  11. Enrolled in the same study at a different time (i.e., each subject can be in the study population only once)
  12. Subject who is legally incompetent, physically or mentality incapable of giving consent (e.g., emergency situation, under guardianship, subject in a social or sanitary establishment, prisoners or subject who are involuntarily incarcerated)
  13. Positive alcohol test and/or history of alcohol abuse that could interfere with subject's participation in study
  14. Positive urine drug tests (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and opiates)
  15. Positive serology test (HbsAg, HCV, HIV)

    Specific to smokers

  16. Subject who has used any nicotine-containing products other than commercially available cigarettes (either a tobacco-based product or nicotine-replacement therapy) as well as electronic cigarettes and similar devices within 1 month prior to the screening visit

    Additionally, women of childbearing potential must be excluded if:

  17. Subject is pregnant (does not have negative pregnancy tests at screening and at admission) or breastfeeding
  18. Subject does not agree to use an acceptable method of effective contraception: intrauterine device, intrauterine system, established use of oral/injectable/implantable/transdermal hormonal methods, barrier methods of contraception (condoms, occlusive caps) with spermicidal foam/gel/film/suppository, vasectomised partner or true abstinence (periodic abstinence and withdrawal are not effective methods) from screening until the end of the safety follow-up period

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01465880

Layout table for location information
United Kingdom
Simbec Research Ltd
Merthyr Tydfil, South Wales, United Kingdom, CF48 4DR
Sponsors and Collaborators
Philip Morris Products S.A.
Layout table for investigator information
Principal Investigator: Salvatore Febbraro, MD Simbec Research
Layout table for additonal information
Responsible Party: Philip Morris Products S.A. Identifier: NCT01465880    
Other Study ID Numbers: PIPA_CEMA_01
First Posted: November 6, 2011    Key Record Dates
Last Update Posted: December 21, 2011
Last Verified: December 2011
Keywords provided by Philip Morris Products S.A.:
Smoking research study